17.05.2014 Views

PEBC Report - Programa de Epigenética y Biología del Cáncer

PEBC Report - Programa de Epigenética y Biología del Cáncer

PEBC Report - Programa de Epigenética y Biología del Cáncer

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

In 2008 Dra Eva Gonzalez Suarez was awar<strong>de</strong>d a Ramon y<br />

Cajal research contract and joined the Cancer Epigenetics<br />

and Biology Program (<strong>PEBC</strong>) integrated in the Biomedical<br />

Research Institute of Bellvitge (IDIBELL) in Barcelona as a<br />

Young Investigator and lea<strong>de</strong>r of the “Transformation and<br />

Metastasis” group. Her current research lines are within the<br />

mammary gland biology and breast cancer field, particularly<br />

in un<strong>de</strong>rstanding the events that drive transformation of the<br />

mammary epithelial cells and metastasis and the stem cell<br />

pathways that become <strong>de</strong>regulated during carcinogenesis.<br />

Research at the “Transformation and Metastasis”<br />

group Overview<br />

Breast cancer is the most common type of cancer in<br />

women with a mortality of 30-40% mainly due to metastasis.<br />

Breast cancer is currently managed by surgery, hormone<br />

therapy, chemotherapy and radiation. However, these<br />

approaches are non-specific, have severe si<strong>de</strong> effects, and<br />

many are ineffective, specially in the treatment of metastatic<br />

disease. Our work in the Transformation and Metastasis<br />

group lead by Eva Gonzalez-Suarez is focused in the i<strong>de</strong>ntification<br />

of the main proteins and pathways that drive mammary<br />

epithelial cell transformation and metastasis in or<strong>de</strong>r to<br />

find targets for future therapeutics and elucidate mechanisms<br />

of resistance to current breast cancer drugs.<br />

Tools and methods<br />

We are generating orthotopic mouse mo<strong>de</strong>ls of breast cancer.<br />

Our aim is to generate mo<strong>de</strong>ls that resemble different<br />

breast cancer subtypes and use them to i<strong>de</strong>ntify new potential<br />

targets for breast cancer treatment, to test novel therapies<br />

and to characterize “in vivo” the mechanisms of resistance<br />

to drugs currently used in the clinics. In addition we<br />

use several transgenic mouse mo<strong>de</strong>ls prone to <strong>de</strong>velop<br />

mammary epithelial tumors to complement the xenograft<br />

mo<strong>de</strong>ls. Our experimental mo<strong>de</strong>ls also inclu<strong>de</strong> three-dimensional<br />

(3D) and suspension cultures of primary mouse and<br />

human breast cancer cells from fresh mouse and human<br />

tumors. 3D mo<strong>de</strong>ls of epithelial cells are physiologically relevant<br />

as they recapitulate the structural organization and<br />

multi-cellular complexity of the mammary epithelia.<br />

Suspension cultures are extensively used to expand and<br />

characterize the population of tumor initiating cells in vitro.<br />

Cancer Epigenetics and Biology Symposium<br />

48 28, 29 May 2009, Barcelona

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!